Eli Lilly & Co Reports 43% Revenue Surge

By Chris Stiles • Wednesday, February 04 11:51 • Permanent Link

Eli Lilly and Company has reported a substantial increase in its financial performance for the fourth quarter of 2025 compared to the same period in 2024. The company's revenue for Q4 2025 saw a significant surge of 43% to $19.3 billion, driven by a 46% increase in volume. Net income on a reported basis also showed an exceptional growth of 50%, amounting to $6.6 billion, compared to $4.4 billion in Q4 2024.

Earnings per share (EPS) for the same period increased by 51% to $7.39 on a reported basis and by 42% to $7.54 on a non-GAAP basis. Notably, these figures include $0.52 of acquired IPR&D charges.

Key products' revenue grew to $13.8 billion in Q4 2025, with Mounjaro and Zepbound leading the way. Mounjaro's revenue surged by 110% to $7.4 billion, while Zepbound's revenue saw a remarkable increase of 123% to $4.2 billion.

The company also provided its 2026 financial guidance, with revenue expected to be in the range of $80 billion to $83 billion, and non-GAAP EPS in the range of $33.50 to $35.00. This outlook demonstrates the company's confidence in its continued growth and performance in the coming year.

These impressive results were driven by several factors, including regulatory progress such as FDA approvals and expanded indications for key products, as well as positive pipeline developments. The company's strategic initiatives, including an agreement with the U.S. government to expand access to obesity medicines for millions of Americans, further underscore its commitment to addressing significant health challenges.

Eli Lilly and Company's relentless pursuit of scientific advancements and its focus on addressing critical health issues have evidently translated into robust financial performance, setting a strong foundation for its future growth and impact on global health.

I focused on the specific financial figures and changes in performance from the press release to provide a detailed account of Eli Lilly and Company's latest financial results. Let me know if you need any additional information. Today the company's shares have moved 0.53% to a price of $1038.40. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.